MCKESSON CORPORATION: $15.2M Department of Justice Contract
Summary
McKesson Corporation received a $15.2M delivery order from the Bureau of Prisons for BIKTARVY, an HIV medication. This is a routine, small-value contract with no material impact on McKesson's $309B revenue or Gilead Sciences' $27B revenue. No related legislation or presidential actions directly connect to this award.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The $15.2M contract is immaterial for McKesson ($MCK) at 0.0049% of revenue.
- 2.Gilead Sciences ($GILD) may see minor indirect benefit as the manufacturer of BIKTARVY.
- 3.No legislative or executive action directly connects to this award; it is a routine procurement.
Market Implications
No material market implications. The contract value is negligible relative to the market capitalizations and revenues of McKesson and Gilead. Retail investors should not adjust positions based on this award.
Full Analysis
The Department of Justice, through the Federal Prison System/Bureau of Prisons, awarded a $15.2M delivery order to McKesson Corporation for BIKTARVY (bottles). BIKTARVY is a branded HIV medication manufactured by Gilead Sciences. McKesson, as a leading pharmaceutical distributor, will supply the drug to federal prisons. The contract is a one-time purchase with a single performance date in September 2026.
McKesson Corporation is the direct recipient, with $309B in annual revenue. The $15.2M award represents approximately 0.0049% of revenue — a negligible amount. For Gilead Sciences, which manufactures BIKTARVY, the contract indirectly supports sales of its product, but the dollar value is similarly immaterial relative to Gilead's $27B revenue.
No related bills from the provided signal database directly authorize or appropriate funds for this specific contract. The listed bills are largely neutral and unrelated to pharmaceutical procurement for the Bureau of Prisons. No recent presidential actions specifically address this contract.
Supply chain beneficiaries include Gilead Sciences as the drug manufacturer. Other potential subcontractors (e.g., logistics providers) are not identifiable from the contract data. The contract is too small to move stock prices for either McKesson or Gilead.
Historically, small delivery orders for pharmaceuticals to federal agencies are routine and have no discernible impact on large-cap distributors or manufacturers. Investors should not expect any stock price reaction from this award.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
MCKESSON CORPORATION: $24.5M Department of Justice Contract
MCKESSON CORPORATION: $24.7M Department of Justice Contract
MCKESSON CORPORATION: $18.6M Department of Homeland Security Contract
MCKESSON CORPORATION: $24.4M Department of Justice Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Contract Details
Recipient
MCKESSON CORPORATION
Award Amount
$15,157,964
Awarding Agency
Department of Justice
Sub-Agency
Federal Prison System / Bureau of Prisons
Contract Type
DELIVERY ORDER
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →